EA201890153A1 - Ингибиторы поглощения глюкозы - Google Patents
Ингибиторы поглощения глюкозыInfo
- Publication number
- EA201890153A1 EA201890153A1 EA201890153A EA201890153A EA201890153A1 EA 201890153 A1 EA201890153 A1 EA 201890153A1 EA 201890153 A EA201890153 A EA 201890153A EA 201890153 A EA201890153 A EA 201890153A EA 201890153 A1 EA201890153 A1 EA 201890153A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compounds
- absorption inhibitors
- glucose absorption
- uptake activity
- transporters
- Prior art date
Links
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title 1
- 238000010521 absorption reaction Methods 0.000 title 1
- 239000008103 glucose Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102100023536 Solute carrier family 2, facilitated glucose transporter member 1 Human genes 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000004190 glucose uptake Effects 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 108020003264 Cotransporters Proteins 0.000 abstract 1
- 102000034534 Cotransporters Human genes 0.000 abstract 1
- 102000042092 Glucose transporter family Human genes 0.000 abstract 1
- 108091052347 Glucose transporter family Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 108010006769 Monosaccharide Transport Proteins Proteins 0.000 abstract 1
- 102000005455 Monosaccharide Transport Proteins Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091006296 SLC2A1 Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000034659 glycolysis Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562185223P | 2015-06-26 | 2015-06-26 | |
| PCT/US2016/039365 WO2016210330A1 (en) | 2015-06-26 | 2016-06-24 | Glucose uptake inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201890153A1 true EA201890153A1 (ru) | 2018-06-29 |
Family
ID=57586425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201890153A EA201890153A1 (ru) | 2015-06-26 | 2016-06-24 | Ингибиторы поглощения глюкозы |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10273248B2 (enExample) |
| EP (1) | EP3313825A4 (enExample) |
| JP (1) | JP2018518518A (enExample) |
| CN (1) | CN108349910A (enExample) |
| CA (1) | CA3028355A1 (enExample) |
| EA (1) | EA201890153A1 (enExample) |
| HK (1) | HK1254835A1 (enExample) |
| WO (1) | WO2016210330A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3573992B1 (en) * | 2017-01-26 | 2022-04-13 | Youla S. Tsantrizos | Substituted bicyclic pyrimidine-based compounds and compositions and uses thereof |
| US11071735B2 (en) | 2017-04-28 | 2021-07-27 | Kadmon Corporation, Llc | Treatment of inflammatory conditions and autoimmune diseases with glucose uptake inhibitors |
| CN109020957B (zh) * | 2017-06-12 | 2023-01-13 | 南京天印健华医药科技有限公司 | 作为mnk抑制剂的杂环化合物 |
| CN110573501B (zh) | 2017-06-30 | 2023-09-29 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
| WO2019000683A1 (zh) | 2017-06-30 | 2019-01-03 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
| AU2018294054B2 (en) | 2017-06-30 | 2022-05-26 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof |
| CN109384782A (zh) * | 2017-08-04 | 2019-02-26 | 厦门大学 | 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途 |
| US10933061B2 (en) | 2017-12-21 | 2021-03-02 | Shepherd Therapeutics, Inc. | Pyrvinium pamoate therapies and methods of use |
| US10689386B2 (en) | 2018-03-07 | 2020-06-23 | Duquesne University Of The Holy Spirit | Pyrazolo[4,3-d]pyrimidines as antitumor agents |
| WO2020005935A1 (en) * | 2018-06-25 | 2020-01-02 | Kadmon Corporation, Llc | Glucose uptake inhibitors |
| WO2021095032A1 (en) * | 2019-11-13 | 2021-05-20 | Metabomed Ltd | Glucose uptake inhibitors and uses thereof |
| BR112022010254A2 (pt) * | 2019-12-02 | 2022-09-06 | Shanghai Yingli Pharm Co Ltd | Composto heterocíclico contendo oxigênio representado pela fórmula i, método para preparar o composto heterocíclico contendo oxigênio, composto, composição farmacêutica e uso composto heterocíclico contendo oxigênio |
| AU2021309876B2 (en) * | 2020-07-14 | 2024-06-27 | Wuhan Ll Science And Technology Development Co., Ltd. | Rock inhibitor, and preparation method therefor and use thereof |
| CN112479913A (zh) * | 2020-11-19 | 2021-03-12 | 安徽修一制药有限公司 | 一种n,n-二乙基氯代乙酰胺的制备方法 |
| CN112741828B (zh) * | 2021-01-08 | 2022-04-26 | 武汉大学 | 药物联用物及其制备方法和用途 |
| CN117843618A (zh) * | 2022-08-29 | 2024-04-09 | 北京沐华生物科技有限责任公司 | 一种ep300/cbp调节剂及其制备方法和用途 |
| CN117820328A (zh) * | 2023-11-21 | 2024-04-05 | 苏州楚凯药业有限公司 | 一种2,4-二氯-6,7-二氢呋喃并[3,2-d]嘧啶的合成方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4505228B2 (ja) * | 2002-01-10 | 2010-07-21 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | Ｒｈｏ−キナーゼ阻害剤 |
| WO2009079412A2 (en) * | 2007-12-14 | 2009-06-25 | Ardea Biosciences Inc. | Reverse transcriptase inhibitors |
| CN102791697A (zh) * | 2009-10-12 | 2012-11-21 | 瑞科西有限公司 | 作为TBKL和/或IKKε抑制剂的氨基-嘧啶化合物 |
| WO2012040499A2 (en) * | 2010-09-22 | 2012-03-29 | Surface Logix, Inc. | Metabolic inhibitors |
| AU2012244550C1 (en) * | 2011-04-21 | 2017-06-22 | Origenis Gmbh | Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors |
| CN102901456B (zh) | 2012-09-12 | 2015-10-28 | 深圳深蓝精机有限公司 | 检测装置及检测圆轴的外径、跳动值、真圆度的方法 |
| EP2903618B1 (en) * | 2012-10-05 | 2022-06-01 | Kadmon Corporation, LLC | Rho kinase inhibitors |
| US10729691B2 (en) * | 2015-06-26 | 2020-08-04 | Kadmon Corporation, Llc | Treatment of infectious diseases with glucose uptake inhibitors |
-
2016
- 2016-06-24 US US15/737,911 patent/US10273248B2/en active Active
- 2016-06-24 CA CA3028355A patent/CA3028355A1/en not_active Abandoned
- 2016-06-24 EP EP16815426.8A patent/EP3313825A4/en not_active Withdrawn
- 2016-06-24 WO PCT/US2016/039365 patent/WO2016210330A1/en not_active Ceased
- 2016-06-24 CN CN201680048825.8A patent/CN108349910A/zh active Pending
- 2016-06-24 EA EA201890153A patent/EA201890153A1/ru unknown
- 2016-06-24 JP JP2017567146A patent/JP2018518518A/ja not_active Ceased
- 2016-06-24 HK HK18113929.9A patent/HK1254835A1/zh unknown
-
2019
- 2019-04-29 US US16/397,043 patent/US10988484B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10988484B2 (en) | 2021-04-27 |
| WO2016210330A1 (en) | 2016-12-29 |
| EP3313825A1 (en) | 2018-05-02 |
| US10273248B2 (en) | 2019-04-30 |
| US20190315772A1 (en) | 2019-10-17 |
| HK1254835A1 (zh) | 2019-07-26 |
| CN108349910A (zh) | 2018-07-31 |
| CA3028355A1 (en) | 2016-12-29 |
| JP2018518518A (ja) | 2018-07-12 |
| US20180298029A1 (en) | 2018-10-18 |
| EP3313825A4 (en) | 2019-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201891983A8 (ru) | Комбинированная терапия антителами к cd73 | |
| PH12020550901A1 (en) | Macrocyclic compounds for treating disease | |
| EA201800367A1 (ru) | Способы лечения болезни хантингтона | |
| EA201892581A1 (ru) | Варианты комбинированной терапии ингибиторами hdac и ингибиторами pd-l1 | |
| EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
| EA201690206A1 (ru) | Терапевтически активные соединения и способы их применения | |
| EA201691845A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
| EA201891732A1 (ru) | Биспецифичные связывающие белки для pd-l1 и kdr | |
| EA201790413A1 (ru) | Антитела против tigit | |
| EA201591382A1 (ru) | Ингибиторы гистондеметилаз | |
| EA201500995A1 (ru) | Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения | |
| EA201892241A1 (ru) | Диарильные макроциклы в качестве модуляторов протеинкиназ | |
| EA201401077A1 (ru) | Биспецифические антитела к человеческому tweak и человеческому il17 и их применения | |
| EA201792028A1 (ru) | Альфа-цинамидные соединения и композиции как ингибиторы hdac8 | |
| EA201691844A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
| EA202090014A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| EA202091360A1 (ru) | Гуманизированные анти-liv1 антитела для лечения рака молочной железы | |
| EA201491811A1 (ru) | АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ | |
| EA201591618A1 (ru) | Замещенные имидазопиридазины | |
| EA201690783A1 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
| EA201592203A1 (ru) | Способы лечения таупатии | |
| EA201692525A1 (ru) | Замещенные соединения [1,2,4]триазола и имидазола в качестве фунгицидов | |
| MX2022007671A (es) | Compuestos antihelminticos que comprenden una estructura de azaindoles. | |
| EA201591996A1 (ru) | Способы и композиции для заживления раны | |
| EA201792287A1 (ru) | Способы лечения рака |